BlackRock Virginia Municipal Bond Trust
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BHV research report →
Price Chart
About the company
The BlackRock Virginia Municipal Bond Trust (BHV) functions as a closed-end mutual fund, concentrating its investments within the fixed-income sector. Launched by BlackRock, Inc. , the fund's investment management is handled by BlackRock Advisors, LLC.
- CEO
- John Perlowski
- IPO
- 2002
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on BHV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.38M
- P/E
- 15.03
- PEG
- 0.00
- P/S
- 13.46
- P/B
- 1.04
- EV/EBITDA
- 17.92
- Div Yield
- 4.82%
- Gross Margin
- 82.28%
- Op Margin
- 125.33%
- Net Margin
- 89.58%
- ROE
- 6.79%
- ROIC
- 5.82%
Latest fiscal year · YoY change
- Revenue
- $1.37M+36.0%
- Gross Profit
- $1.12M+51.2%
- Op Income
- $1.71M
- Net Income
- $1.22M+181.9%
- EPS
- $0.77+181.9%
- OCF Growth
- -17.1%
- FCF Growth
- -17.1%
- 52W High
- $15.15
- 52W Low
- $10.04
- 50D MA
- $12.43
- 200D MA
- $11.55
- Beta
- 0.99
- RSI (14)
- 43
- Avg Volume
- 4.57K
No earnings-call transcripts are available for BHV yet.
- Free Float
- 99.8%
- Shares Outstanding
- 1.59M
- Float Shares
- 1.58M
of shares held by institutions
9 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cassaday & Co Wealth Management LLC | 27.80K | ▲ 27.80K |
| Morgan Stanley | 27.31K | ▲ 173 |
| D'Orazio & Associates, Inc. | 16.90K | 0 |
| Cetera Investment Advisers | 14.53K | ▲ 14.53K |
| Lpl Financial LLC | 11.37K | ▲ 11.37K |
| Cerity Partners LLC | 10.42K | ▲ 10.42K |
| Geneos Wealth Management Inc. | 7.70K | 0 |
| Ubs Group AG | 5.14K | ▼ 69 |
| Advisor Group Holdings, Inc. | 4.10K | 0 |
| Royal Bank Of Canada | 2.37K | ▲ 2.37K |
| Steward Partners Investment Advisory, LLC | 2.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Mahoney Francis C. | other | 0 |
| Aug 1, 26 | Park Charles | other | 0 |
| May 8, 25 | Minar Stephen Thomas | other | 0 |
| Sep 9, 23 | Steinmetz Arthur Philip | other | 0 |
| Jul 1, 23 | Wasserman Aaron David | other | 0 |
| Mar 1, 23 | KALINOSKI MICHAEL | other | 0 |
| Mar 1, 23 | Santiago Kristi Manidis | other | 0 |
| Mar 1, 23 | OCONNOR WALTER | other | 0 |
| Sep 29, 22 | Romaglino Christian | other | 0 |
| Jun 16, 20 | Toronto Dominion Investments, Inc. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BHV coverage
Recent articles, reports, and earnings notes.
No research on BHV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BHV report →Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
prnewswire.com · Oct 8
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
prnewswire.com · Sep 28
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV) Shares Pass Below 50 Day Moving Average – Here’s What Happened
defenseworld.net · Sep 5
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
seekingalpha.com · Aug 27
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
prnewswire.com · Aug 10
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
prnewswire.com · Jul 20
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
seekingalpha.com · Jul 13
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
prnewswire.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.